{"id":"bendamustin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Pyrexia","drugRate":"24%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"20%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"16%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Weight decreased","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Hyperuricemia","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Nasopharyngitis","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Hypersensitivity","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Infection","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Chills","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Herpes simplex","drugRate":"3%","severity":"common","organSystem":""}],"contraindications":["Acute infectious disease","Acute nephropathy","Anemia","Bone marrow depression","Breastfeeding (mother)","Chemotherapy-Induced Hyperuricemia","Disease of liver","Fluid volume disorder","Hepatic failure","Hyperkalemia","Kidney disease","Neutropenic disorder","Pregnancy, function","Smokes tobacco daily","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Hypertensive crisis","drugRate":"1.96%","severity":"serious"},{"effect":"Pyrexia (Grade 3/4)","drugRate":"3.92%","severity":"serious"},{"effect":"Infection (Grade 3/4)","drugRate":"1.96%","severity":"serious"},{"effect":"Hyperuricemia (Grade 3/4)","drugRate":"1.96%","severity":"serious"},{"effect":"Rash (Grade 3/4)","drugRate":"2.61%","severity":"serious"},{"effect":"Hypersensitivity (Grade 3/4)","drugRate":"1.31%","severity":"serious"},{"effect":"Nausea (Grade 3/4)","drugRate":"0.65%","severity":"serious"},{"effect":"Vomiting (Grade 3/4)","drugRate":"0.65%","severity":"serious"},{"effect":"Diarrhea (Grade 3/4)","drugRate":"1.31%","severity":"serious"},{"effect":"Fatigue (Grade 3/4)","drugRate":"1.31%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL487253","moleculeType":"Small molecule","molecularWeight":"358.27"},"aliases":["Ribomustin","Bendamustine hydrochloride","CEP-18083","TREANDA"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"766b73e2-49bb-47f9-bbb1-44cfa1a3197e","title":"BENDAMUSTINE HYDROCHLORIDE INJECTION [BAXTER HEALTHCARE CORPORATION]"},"ecosystem":[],"mechanism":{"target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2"},"_scrapedAt":"2026-03-28T01:03:55.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Bendamustine","title":"Bendamustine","extract":"Bendamustine, sold under the brand name Treanda among others, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein."},"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic lymphoid leukemia, disease","diseaseId":"chronic-lymphoid-leukemia-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diffuse large B-cell lymphoma refractory","diseaseId":"diffuse-large-b-cell-lymphoma-refractory","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Follicular non-Hodgkin's lymphoma","diseaseId":"follicular-non-hodgkin's-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Indolent B-Cell Lymphoma","diseaseId":"indolent-b-cell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Treatment prior to tumor-specific T-cell infusion therapy","diseaseId":"treatment-prior-to-tumor-specific-t-cell-infusion-therapy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT01886872","phase":"PHASE3","title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-15","conditions":"Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia","enrollment":547},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT07139873","phase":"PHASE3","title":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","status":"RECRUITING","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","startDate":"2025-09-08","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":250},{"nctId":"NCT07492407","phase":"","title":"CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04","conditions":"MZL","enrollment":131},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT01479842","phase":"PHASE1","title":"Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kami Maddocks, MD","startDate":"2014-03-26","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT04629729","phase":"PHASE1","title":"FT819 in Subjects With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fate Therapeutics","startDate":"2021-07-12","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT07477639","phase":"PHASE1, PHASE2","title":"Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Tr1X, Inc.","startDate":"2026-03","conditions":"Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis","enrollment":39},{"nctId":"NCT06846671","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-04-10","conditions":"CLL, Chronic Lymphocytic Leukemia","enrollment":250},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT06483048","phase":"PHASE1","title":"MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-09-20","conditions":"Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma","enrollment":12},{"nctId":"NCT05624554","phase":"PHASE3","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-16","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":300},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT06308978","phase":"PHASE1","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-03-28","conditions":"Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)","enrollment":244},{"nctId":"NCT03336333","phase":"PHASE3","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2017-10-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":590},{"nctId":"NCT07225985","phase":"PHASE1, PHASE2","title":"Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-05-01","conditions":"Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma","enrollment":50},{"nctId":"NCT07450508","phase":"PHASE3","title":"Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-04-30","conditions":"Classical Hodgkin Lymphoma Relapsed","enrollment":88},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":"Lymphoma","enrollment":182},{"nctId":"NCT06504940","phase":"PHASE2","title":"Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-28","conditions":"Marginal Zone Lymphoma","enrollment":69},{"nctId":"NCT06138132","phase":"PHASE1","title":"A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-04-10","conditions":"Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive","enrollment":12},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":"Hodgkin Lymphoma","enrollment":232},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":60},{"nctId":"NCT02972840","phase":"PHASE3","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-04-05","conditions":"Lymphoma, Mantle Cell","enrollment":635},{"nctId":"NCT05551936","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaishalee Kenkre","startDate":"2023-01-26","conditions":"Follicular Lymphoma","enrollment":42},{"nctId":"NCT06191887","phase":"PHASE1","title":"B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-18","conditions":"B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":27},{"nctId":"NCT06522737","phase":"PHASE3","title":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","status":"RECRUITING","sponsor":"SecuraBio","startDate":"2025-05-19","conditions":"Lymphoma","enrollment":124},{"nctId":"NCT04674813","phase":"PHASE1","title":"A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2021-02-24","conditions":"Multiple Myeloma","enrollment":130},{"nctId":"NCT02970318","phase":"PHASE3","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-02-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":310},{"nctId":"NCT04624906","phase":"PHASE2","title":"Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-03-02","conditions":"Waldenstrom Macroglobulinemia","enrollment":63},{"nctId":"NCT05300282","phase":"PHASE1, PHASE2","title":"Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-02-27","conditions":"Relapsed or Refractory Hodgkin's Lymphoma","enrollment":122},{"nctId":"NCT05023980","phase":"PHASE3","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-09-23","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":309},{"nctId":"NCT04223765","phase":"PHASE1","title":"Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2020-11-12","conditions":"Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma","enrollment":20},{"nctId":"NCT02717624","phase":"PHASE1","title":"A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-04-20","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":72},{"nctId":"NCT05508867","phase":"PHASE2","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-10-18","conditions":"Hodgkin Lymphoma","enrollment":203},{"nctId":"NCT04022239","phase":"PHASE1, PHASE2","title":"Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-13","conditions":"Hematopoietic and Lymphoid System Neoplasm","enrollment":25},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":"Lymphoma, Follicular","enrollment":90},{"nctId":"NCT06970743","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-05-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":150},{"nctId":"NCT03602157","phase":"PHASE1","title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-12-12","conditions":"Lymphoma, Immune System Diseases, Immunoproliferative Disorders","enrollment":43},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT05816850","phase":"","title":"Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-09-19","conditions":"Follicular Lymphoma","enrollment":654},{"nctId":"NCT07166549","phase":"PHASE1","title":"Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-06","conditions":"B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma","enrollment":12},{"nctId":"NCT06043713","phase":"PHASE1","title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-15","conditions":"Metastatic Malignant Solid Neoplasm","enrollment":24},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":"Marginal Zone Lymphoma","enrollment":260},{"nctId":"NCT07189065","phase":"PHASE2","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2025-11-27","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT05182073","phase":"PHASE1","title":"FT576 in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2021-11-10","conditions":"Multiple Myeloma, Myeloma","enrollment":31},{"nctId":"NCT06241456","phase":"PHASE1","title":"FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-01-05","conditions":"Advanced Solid Tumor","enrollment":351},{"nctId":"NCT03696784","phase":"PHASE1","title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Lymphoma, Lymphoma, B-Cell, Immune System Diseases","enrollment":19},{"nctId":"NCT03567876","phase":"PHASE2","title":"Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2018-09-03","conditions":"Lymphoma, Mantle-Cell","enrollment":141},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT03352765","phase":"PHASE1","title":"A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-20","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT07259122","phase":"PHASE2","title":"A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-30","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":43},{"nctId":"NCT06561347","phase":"PHASE2","title":"Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-12-20","conditions":"Waldenstrom Macroglobulinemia","enrollment":55},{"nctId":"NCT01286272","phase":"PHASE2","title":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-04-28","conditions":"Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":135},{"nctId":"NCT07145125","phase":"","title":"Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2025-02-01","conditions":"Relapsed or Refractory Hodgkin Lymphoma","enrollment":222},{"nctId":"NCT07238712","phase":"PHASE2","title":"Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2025-05-10","conditions":"Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","enrollment":60},{"nctId":"NCT02996773","phase":"PHASE1","title":"Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2016-11-29","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT06090864","phase":"PHASE1, PHASE2","title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-04-25","conditions":"Hodgkin Lymphoma, Relapse, Refractory","enrollment":31},{"nctId":"NCT03856216","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-28","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm","enrollment":15},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT02315157","phase":"PHASE1","title":"Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2014-06","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":""},{"nctId":"NCT07208981","phase":"PHASE2","title":"Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-14","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":169},{"nctId":"NCT02153580","phase":"PHASE1","title":"Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-09-24","conditions":"B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified","enrollment":37},{"nctId":"NCT07206264","phase":"PHASE2","title":"Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-10","conditions":"Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT04002297","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2019-08-20","conditions":"Mantle Cell Lymphoma; Non-Hodgkin Lymphoma","enrollment":510},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":"Follicular Lymphoma","enrollment":1030},{"nctId":"NCT04083495","phase":"PHASE2","title":"CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-17","conditions":"Peripheral T Cell Lymphoma","enrollment":20},{"nctId":"NCT07169565","phase":"PHASE1","title":"Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-01","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":21},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT07059650","phase":"PHASE1, PHASE2","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-08-19","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":150},{"nctId":"NCT05950334","phase":"PHASE1","title":"FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2023-11-16","conditions":"Relapsed/Refractory B-Cell Lymphoma","enrollment":20},{"nctId":"NCT03039114","phase":"PHASE1","title":"Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-02-15","conditions":"Lymphoma","enrollment":26},{"nctId":"NCT03424122","phase":"PHASE1","title":"INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-07-02","conditions":"B-cell Lymphoma","enrollment":50},{"nctId":"NCT07126678","phase":"NA","title":"Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-07-15","conditions":"Follicular Lymphoma, Treatment Naive","enrollment":15},{"nctId":"NCT03834688","phase":"PHASE2","title":"Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2020-01-13","conditions":"Mantle Cell Lymphoma","enrollment":33},{"nctId":"NCT04433182","phase":"PHASE2","title":"Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2020-08-18","conditions":"Diffuse Large B-cell Lymphoma","enrollment":37},{"nctId":"NCT03739619","phase":"PHASE1, PHASE2","title":"Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-11-26","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT03872180","phase":"PHASE2","title":"Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-04-11","conditions":"CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive","enrollment":23},{"nctId":"NCT02278796","phase":"PHASE2","title":"A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":108},{"nctId":"NCT07072221","phase":"NA","title":"Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-11-01","conditions":"Peripheral T-cell Lymphoma","enrollment":40},{"nctId":"NCT02763319","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-11-28","conditions":"Diffuse Large B-cell Lymphoma","enrollment":453},{"nctId":"NCT05451771","phase":"PHASE1, PHASE2","title":"Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis","status":"RECRUITING","sponsor":"Rajshekhar Chakraborty, MD","startDate":"2022-10-26","conditions":"AL Amyloidosis","enrollment":53},{"nctId":"NCT01776840","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-05-16","conditions":"Mantle Cell Lymphoma","enrollment":523},{"nctId":"NCT04892277","phase":"PHASE1","title":"CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-10-03","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma","enrollment":25},{"nctId":"NCT05025423","phase":"PHASE2","title":"Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-21","conditions":"Mantle Cell Lymphoma","enrollment":7},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":"Hairy Cell Leukemia","enrollment":69},{"nctId":"NCT04673617","phase":"PHASE1, PHASE2","title":"AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2021-03-29","conditions":"Non Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT02414022","phase":"","title":"Economic Analysis of Alliance A041202 CLL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-04-15","conditions":"Chronic Lymphocytic Leukemia","enrollment":55},{"nctId":"NCT04515238","phase":"PHASE2","title":"Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"German CLL Study Group","startDate":"2020-10-01","conditions":"Chronic Lymphoid Leukemia","enrollment":42},{"nctId":"NCT02401503","phase":"PHASE2","title":"Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2015-05-06","conditions":"Chronic Lymphocytic Leucemia","enrollment":66},{"nctId":"NCT04727151","phase":"PHASE1, PHASE2","title":"TAC T-cells for the Treatment of HER2-positive Solid Tumors","status":"TERMINATED","sponsor":"Triumvira Immunologics, Inc.","startDate":"2021-04-19","conditions":"HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer","enrollment":28},{"nctId":"NCT07008053","phase":"PHASE2","title":"BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-07","conditions":"Marginal Zone Lymphomas","enrollment":37}],"_emaApprovals":[],"_faersSignals":[{"count":11,"reaction":"PYREXIA"},{"count":7,"reaction":"DISEASE PROGRESSION"},{"count":7,"reaction":"PLASMA CELL MYELOMA"},{"count":6,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":5,"reaction":"FEBRILE NEUTROPENIA"},{"count":5,"reaction":"NEUTROPENIA"},{"count":5,"reaction":"OFF LABEL USE"},{"count":5,"reaction":"THROMBOCYTOPENIA"},{"count":4,"reaction":"ANAEMIA"},{"count":4,"reaction":"CYTOMEGALOVIRUS INFECTION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":41,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Bendamustin","genericName":"Bendamustin","companyName":"Meir Medical Center","companyId":"meir-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":8,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}